Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. RXRX Peers
See (RXRX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RXRX | $5.19 | -3.91% | 2B | -2.79 | -$1.80 | N/A |
| VRTX | $444.84 | +0.32% | 113.3B | -114.92 | -$3.84 | N/A |
| REGN | $523.11 | +0.40% | 55.3B | 13.24 | $39.35 | +0.17% |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $322.03 | +1.19% | 42.1B | -153.00 | -$2.11 | N/A |
| ARGX | $554.26 | -1.03% | 34.2B | 34.18 | $16.39 | N/A |
| BNTX | $107.14 | +0.94% | 25.7B | -29.16 | -$3.66 | N/A |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| RPRX | $36.04 | +2.18% | 20.2B | 14.64 | $2.45 | +2.42% |
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
Stock Comparison
RXRX vs VRTX Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, VRTX has a market cap of 113.3B. Regarding current trading prices, RXRX is priced at $5.19, while VRTX trades at $444.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas VRTX's P/E ratio is -114.92. In terms of profitability, RXRX's ROE is -0.75%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, RXRX is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs REGN Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, REGN has a market cap of 55.3B. Regarding current trading prices, RXRX is priced at $5.19, while REGN trades at $523.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas REGN's P/E ratio is 13.24. In terms of profitability, RXRX's ROE is -0.75%, compared to REGN's ROE of +0.15%. Regarding short-term risk, RXRX is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs SGEN Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, RXRX is priced at $5.19, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas SGEN's P/E ratio is -57.19. In terms of profitability, RXRX's ROE is -0.75%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, RXRX is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs ALNY Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, ALNY has a market cap of 42.1B. Regarding current trading prices, RXRX is priced at $5.19, while ALNY trades at $322.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas ALNY's P/E ratio is -153.00. In terms of profitability, RXRX's ROE is -0.75%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, RXRX is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs ARGX Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, ARGX has a market cap of 34.2B. Regarding current trading prices, RXRX is priced at $5.19, while ARGX trades at $554.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas ARGX's P/E ratio is 34.18. In terms of profitability, RXRX's ROE is -0.75%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, RXRX is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs BNTX Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, BNTX has a market cap of 25.7B. Regarding current trading prices, RXRX is priced at $5.19, while BNTX trades at $107.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas BNTX's P/E ratio is -29.16. In terms of profitability, RXRX's ROE is -0.75%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, RXRX is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs BGNE Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, RXRX is priced at $5.19, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas BGNE's P/E ratio is -22.55. In terms of profitability, RXRX's ROE is -0.75%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, RXRX is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs RPRX Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, RPRX has a market cap of 20.2B. Regarding current trading prices, RXRX is priced at $5.19, while RPRX trades at $36.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas RPRX's P/E ratio is 14.64. In terms of profitability, RXRX's ROE is -0.75%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, RXRX is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs DNA-WT Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, RXRX is priced at $5.19, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, RXRX's ROE is -0.75%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, RXRX is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.
RXRX vs SMMT Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, SMMT has a market cap of 15.3B. Regarding current trading prices, RXRX is priced at $5.19, while SMMT trades at $20.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas SMMT's P/E ratio is -60.68. In terms of profitability, RXRX's ROE is -0.75%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, RXRX is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs INCY Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, INCY has a market cap of 13.2B. Regarding current trading prices, RXRX is priced at $5.19, while INCY trades at $68.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas INCY's P/E ratio is 341.85. In terms of profitability, RXRX's ROE is -0.75%, compared to INCY's ROE of +0.01%. Regarding short-term risk, RXRX is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs UTHR Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, UTHR has a market cap of 12.8B. Regarding current trading prices, RXRX is priced at $5.19, while UTHR trades at $288.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas UTHR's P/E ratio is 11.33. In terms of profitability, RXRX's ROE is -0.75%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, RXRX is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs GMAB Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, GMAB has a market cap of 12.7B. Regarding current trading prices, RXRX is priced at $5.19, while GMAB trades at $20.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas GMAB's P/E ratio is 12.06. In terms of profitability, RXRX's ROE is -0.75%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, RXRX is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs KRTX Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, RXRX is priced at $5.19, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas KRTX's P/E ratio is -28.09. In terms of profitability, RXRX's ROE is -0.75%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, RXRX is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs EXEL Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, EXEL has a market cap of 11.9B. Regarding current trading prices, RXRX is priced at $5.19, while EXEL trades at $43.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas EXEL's P/E ratio is 19.94. In terms of profitability, RXRX's ROE is -0.75%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, RXRX is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs BMRN Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, BMRN has a market cap of 10.6B. Regarding current trading prices, RXRX is priced at $5.19, while BMRN trades at $54.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas BMRN's P/E ratio is 20.43. In terms of profitability, RXRX's ROE is -0.75%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, RXRX is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs MRNA Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, MRNA has a market cap of 10.5B. Regarding current trading prices, RXRX is priced at $5.19, while MRNA trades at $27.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas MRNA's P/E ratio is -3.11. In terms of profitability, RXRX's ROE is -0.75%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, RXRX is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs ASND Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, ASND has a market cap of 10.4B. Regarding current trading prices, RXRX is priced at $5.19, while ASND trades at $171.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas ASND's P/E ratio is -25.83. In terms of profitability, RXRX's ROE is -0.75%, compared to ASND's ROE of +1.91%. Regarding short-term risk, RXRX is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs RXDX Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, RXRX is priced at $5.19, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas RXDX's P/E ratio is -56.47. In terms of profitability, RXRX's ROE is -0.75%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, RXRX is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs IMGN Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, RXRX is priced at $5.19, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas IMGN's P/E ratio is -111.55. In terms of profitability, RXRX's ROE is -0.75%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, RXRX is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs BBIO Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, BBIO has a market cap of 8.5B. Regarding current trading prices, RXRX is priced at $5.19, while BBIO trades at $43.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas BBIO's P/E ratio is -12.60. In terms of profitability, RXRX's ROE is -0.75%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, RXRX is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs BPMC Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, BPMC has a market cap of 8.3B. Regarding current trading prices, RXRX is priced at $5.19, while BPMC trades at $128.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas BPMC's P/E ratio is -51.24. In terms of profitability, RXRX's ROE is -0.75%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, RXRX is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs CERE Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, RXRX is priced at $5.19, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas CERE's P/E ratio is -16.47. In terms of profitability, RXRX's ROE is -0.75%, compared to CERE's ROE of -0.43%. Regarding short-term risk, RXRX is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs TECH Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, TECH has a market cap of 8.1B. Regarding current trading prices, RXRX is priced at $5.19, while TECH trades at $51.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas TECH's P/E ratio is 62.46. In terms of profitability, RXRX's ROE is -0.75%, compared to TECH's ROE of +0.06%. Regarding short-term risk, RXRX is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs VRNA Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, VRNA has a market cap of 8B. Regarding current trading prices, RXRX is priced at $5.19, while VRNA trades at $95.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas VRNA's P/E ratio is -46.91. In terms of profitability, RXRX's ROE is -0.75%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, RXRX is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs ROIVW Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, RXRX is priced at $5.19, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, RXRX's ROE is -0.75%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, RXRX is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.
RXRX vs CORT Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, CORT has a market cap of 7.8B. Regarding current trading prices, RXRX is priced at $5.19, while CORT trades at $73.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas CORT's P/E ratio is 63.67. In terms of profitability, RXRX's ROE is -0.75%, compared to CORT's ROE of +0.20%. Regarding short-term risk, RXRX is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs ROIV Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, ROIV has a market cap of 7.7B. Regarding current trading prices, RXRX is priced at $5.19, while ROIV trades at $11.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas ROIV's P/E ratio is -15.19. In terms of profitability, RXRX's ROE is -0.75%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, RXRX is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs RVMD Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, RVMD has a market cap of 6.9B. Regarding current trading prices, RXRX is priced at $5.19, while RVMD trades at $37.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas RVMD's P/E ratio is -9.20. In terms of profitability, RXRX's ROE is -0.75%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, RXRX is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs MDGL Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, MDGL has a market cap of 6.7B. Regarding current trading prices, RXRX is priced at $5.19, while MDGL trades at $302.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas MDGL's P/E ratio is -16.87. In terms of profitability, RXRX's ROE is -0.75%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, RXRX is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs RETA Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, RXRX is priced at $5.19, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas RETA's P/E ratio is -66.29. In terms of profitability, RXRX's ROE is -0.75%, compared to RETA's ROE of +0.47%. Regarding short-term risk, RXRX is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs AMRN Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, AMRN has a market cap of 6.5B. Regarding current trading prices, RXRX is priced at $5.19, while AMRN trades at $16.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas AMRN's P/E ratio is -3.57. In terms of profitability, RXRX's ROE is -0.75%, compared to AMRN's ROE of -0.17%. Regarding short-term risk, RXRX is more volatile compared to AMRN. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs JAZZ Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, JAZZ has a market cap of 6.5B. Regarding current trading prices, RXRX is priced at $5.19, while JAZZ trades at $106.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas JAZZ's P/E ratio is 14.52. In terms of profitability, RXRX's ROE is -0.75%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, RXRX is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs HALO Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, HALO has a market cap of 6.4B. Regarding current trading prices, RXRX is priced at $5.19, while HALO trades at $52.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas HALO's P/E ratio is 13.89. In terms of profitability, RXRX's ROE is -0.75%, compared to HALO's ROE of +1.22%. Regarding short-term risk, RXRX is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs IONS Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, IONS has a market cap of 6.3B. Regarding current trading prices, RXRX is priced at $5.19, while IONS trades at $39.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas IONS's P/E ratio is -13.31. In terms of profitability, RXRX's ROE is -0.75%, compared to IONS's ROE of -0.92%. Regarding short-term risk, RXRX is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs TGTX Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, TGTX has a market cap of 5.8B. Regarding current trading prices, RXRX is priced at $5.19, while TGTX trades at $36.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas TGTX's P/E ratio is 146.88. In terms of profitability, RXRX's ROE is -0.75%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, RXRX is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs ABCM Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, RXRX is priced at $5.19, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, RXRX's ROE is -0.75%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, RXRX is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs ISEE Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, RXRX is priced at $5.19, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas ISEE's P/E ratio is -22.44. In terms of profitability, RXRX's ROE is -0.75%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, RXRX is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs TLX Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, TLX has a market cap of 5.4B. Regarding current trading prices, RXRX is priced at $5.19, while TLX trades at $16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas TLX's P/E ratio is 177.67. In terms of profitability, RXRX's ROE is -0.75%, compared to TLX's ROE of +0.14%. Regarding short-term risk, RXRX is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs NUVL Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, NUVL has a market cap of 5.3B. Regarding current trading prices, RXRX is priced at $5.19, while NUVL trades at $78.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas NUVL's P/E ratio is -18.03. In terms of profitability, RXRX's ROE is -0.75%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, RXRX is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs AXSM Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, AXSM has a market cap of 5.1B. Regarding current trading prices, RXRX is priced at $5.19, while AXSM trades at $103.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas AXSM's P/E ratio is -17.91. In terms of profitability, RXRX's ROE is -0.75%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, RXRX is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs ALKS Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, ALKS has a market cap of 4.8B. Regarding current trading prices, RXRX is priced at $5.19, while ALKS trades at $28.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas ALKS's P/E ratio is 13.72. In terms of profitability, RXRX's ROE is -0.75%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, RXRX is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs AKRO Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, RXRX is priced at $5.19, while AKRO trades at $54.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas AKRO's P/E ratio is -14.98. In terms of profitability, RXRX's ROE is -0.75%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, RXRX is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs ALPN Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, RXRX is priced at $5.19, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas ALPN's P/E ratio is -101.52. In terms of profitability, RXRX's ROE is -0.75%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, RXRX is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs ADMA Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, ADMA has a market cap of 4.3B. Regarding current trading prices, RXRX is priced at $5.19, while ADMA trades at $18.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas ADMA's P/E ratio is 21.62. In terms of profitability, RXRX's ROE is -0.75%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, RXRX is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs PCVX Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, PCVX has a market cap of 4.2B. Regarding current trading prices, RXRX is priced at $5.19, while PCVX trades at $33.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas PCVX's P/E ratio is -8.17. In terms of profitability, RXRX's ROE is -0.75%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, RXRX is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs OPT Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, RXRX is priced at $5.19, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas OPT's P/E ratio is -1.52. In terms of profitability, RXRX's ROE is -0.75%, compared to OPT's ROE of +2.60%. Regarding short-term risk, RXRX is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs SLNO Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, SLNO has a market cap of 4.2B. Regarding current trading prices, RXRX is priced at $5.19, while SLNO trades at $86.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas SLNO's P/E ratio is -17.56. In terms of profitability, RXRX's ROE is -0.75%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, RXRX is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs MRTX Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, RXRX is priced at $5.19, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas MRTX's P/E ratio is -4.82. In terms of profitability, RXRX's ROE is -0.75%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, RXRX is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs CRSP Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, CRSP has a market cap of 4.1B. Regarding current trading prices, RXRX is priced at $5.19, while CRSP trades at $49.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas CRSP's P/E ratio is -10.58. In terms of profitability, RXRX's ROE is -0.75%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, RXRX is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.
RXRX vs KRYS Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, KRYS has a market cap of 4B. Regarding current trading prices, RXRX is priced at $5.19, while KRYS trades at $137.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas KRYS's P/E ratio is 33.30. In terms of profitability, RXRX's ROE is -0.75%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, RXRX is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs RYTM Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, RYTM has a market cap of 4B. Regarding current trading prices, RXRX is priced at $5.19, while RYTM trades at $63.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas RYTM's P/E ratio is -22.40. In terms of profitability, RXRX's ROE is -0.75%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, RXRX is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs CYTK Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, CYTK has a market cap of 4B. Regarding current trading prices, RXRX is priced at $5.19, while CYTK trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas CYTK's P/E ratio is -6.27. In terms of profitability, RXRX's ROE is -0.75%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, RXRX is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs PTCT Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, PTCT has a market cap of 4B. Regarding current trading prices, RXRX is priced at $5.19, while PTCT trades at $49.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas PTCT's P/E ratio is 7.66. In terms of profitability, RXRX's ROE is -0.75%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, RXRX is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs MRUS Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, MRUS has a market cap of 3.9B. Regarding current trading prices, RXRX is priced at $5.19, while MRUS trades at $53.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas MRUS's P/E ratio is -12.72. In terms of profitability, RXRX's ROE is -0.75%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, RXRX is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs ZLAB Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, ZLAB has a market cap of 3.8B. Regarding current trading prices, RXRX is priced at $5.19, while ZLAB trades at $35.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas ZLAB's P/E ratio is -13.90. In terms of profitability, RXRX's ROE is -0.75%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, RXRX is less volatile compared to ZLAB. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.
RXRX vs RYZB Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, RXRX is priced at $5.19, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas RYZB's P/E ratio is -57.86. In terms of profitability, RXRX's ROE is -0.75%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, RXRX is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs CBAY Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, RXRX is priced at $5.19, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas CBAY's P/E ratio is -32.81. In terms of profitability, RXRX's ROE is -0.75%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, RXRX is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs ACAD Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, RXRX is priced at $5.19, while ACAD trades at $21.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas ACAD's P/E ratio is 16.15. In terms of profitability, RXRX's ROE is -0.75%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, RXRX is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs ACLX Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, ACLX has a market cap of 3.6B. Regarding current trading prices, RXRX is priced at $5.19, while ACLX trades at $65.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas ACLX's P/E ratio is -21.86. In terms of profitability, RXRX's ROE is -0.75%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, RXRX is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs SWTX Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, RXRX is priced at $5.19, while SWTX trades at $47.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas SWTX's P/E ratio is -13.78. In terms of profitability, RXRX's ROE is -0.75%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, RXRX is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs RNA Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, RNA has a market cap of 3.5B. Regarding current trading prices, RXRX is priced at $5.19, while RNA trades at $29.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas RNA's P/E ratio is -9.68. In terms of profitability, RXRX's ROE is -0.75%, compared to RNA's ROE of -0.27%. Regarding short-term risk, RXRX is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs RARE Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, RARE has a market cap of 3.5B. Regarding current trading prices, RXRX is priced at $5.19, while RARE trades at $36.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas RARE's P/E ratio is -6.26. In terms of profitability, RXRX's ROE is -0.75%, compared to RARE's ROE of -1.86%. Regarding short-term risk, RXRX is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs PTGX Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, PTGX has a market cap of 3.5B. Regarding current trading prices, RXRX is priced at $5.19, while PTGX trades at $56.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas PTGX's P/E ratio is 71.40. In terms of profitability, RXRX's ROE is -0.75%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, RXRX is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs AAPG Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, AAPG has a market cap of 3.4B. Regarding current trading prices, RXRX is priced at $5.19, while AAPG trades at $39.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas AAPG's P/E ratio is -52.80. In terms of profitability, RXRX's ROE is -0.75%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, RXRX is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs SRRK Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, SRRK has a market cap of 3.4B. Regarding current trading prices, RXRX is priced at $5.19, while SRRK trades at $35.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas SRRK's P/E ratio is -14.04. In terms of profitability, RXRX's ROE is -0.75%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, RXRX is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs LEGN Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, LEGN has a market cap of 3.2B. Regarding current trading prices, RXRX is priced at $5.19, while LEGN trades at $36.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas LEGN's P/E ratio is -29.35. In terms of profitability, RXRX's ROE is -0.75%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, RXRX is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs MLTX Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, MLTX has a market cap of 3B. Regarding current trading prices, RXRX is priced at $5.19, while MLTX trades at $47.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas MLTX's P/E ratio is -20.69. In terms of profitability, RXRX's ROE is -0.75%, compared to MLTX's ROE of -0.31%. Regarding short-term risk, RXRX is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs MTSR Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, MTSR has a market cap of 3B. Regarding current trading prices, RXRX is priced at $5.19, while MTSR trades at $28.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas MTSR's P/E ratio is -11.26. In terms of profitability, RXRX's ROE is -0.75%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, RXRX is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs VKTX Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, VKTX has a market cap of 3B. Regarding current trading prices, RXRX is priced at $5.19, while VKTX trades at $26.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas VKTX's P/E ratio is -22.86. In terms of profitability, RXRX's ROE is -0.75%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, RXRX is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.
RXRX vs KYMR Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, KYMR has a market cap of 2.9B. Regarding current trading prices, RXRX is priced at $5.19, while KYMR trades at $44.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas KYMR's P/E ratio is -14.19. In terms of profitability, RXRX's ROE is -0.75%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, RXRX is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs MORF Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, RXRX is priced at $5.19, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas MORF's P/E ratio is -14.88. In terms of profitability, RXRX's ROE is -0.75%, compared to MORF's ROE of -0.22%. Regarding short-term risk, RXRX is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs MOR Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, RXRX is priced at $5.19, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas MOR's P/E ratio is -12.64. In terms of profitability, RXRX's ROE is -0.75%, compared to MOR's ROE of +2.51%. Regarding short-term risk, RXRX is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs CRNX Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, CRNX has a market cap of 2.8B. Regarding current trading prices, RXRX is priced at $5.19, while CRNX trades at $29.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas CRNX's P/E ratio is -7.92. In terms of profitability, RXRX's ROE is -0.75%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, RXRX is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs IMVT Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, IMVT has a market cap of 2.8B. Regarding current trading prices, RXRX is priced at $5.19, while IMVT trades at $16.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas IMVT's P/E ratio is -5.90. In terms of profitability, RXRX's ROE is -0.75%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, RXRX is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs KDNY Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, RXRX is priced at $5.19, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas KDNY's P/E ratio is -12.47. In terms of profitability, RXRX's ROE is -0.75%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, RXRX is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs CPRX Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, CPRX has a market cap of 2.7B. Regarding current trading prices, RXRX is priced at $5.19, while CPRX trades at $21.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas CPRX's P/E ratio is 13.87. In terms of profitability, RXRX's ROE is -0.75%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, RXRX is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs MYOV Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, RXRX is priced at $5.19, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas MYOV's P/E ratio is -14.05. In terms of profitability, RXRX's ROE is -0.75%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, RXRX is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs APGE Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, APGE has a market cap of 2.6B. Regarding current trading prices, RXRX is priced at $5.19, while APGE trades at $44.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas APGE's P/E ratio is -12.02. In terms of profitability, RXRX's ROE is -0.75%, compared to APGE's ROE of -0.19%. Regarding short-term risk, RXRX is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs MIRM Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, MIRM has a market cap of 2.5B. Regarding current trading prices, RXRX is priced at $5.19, while MIRM trades at $51.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas MIRM's P/E ratio is -31.73. In terms of profitability, RXRX's ROE is -0.75%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, RXRX is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs XENE Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, XENE has a market cap of 2.5B. Regarding current trading prices, RXRX is priced at $5.19, while XENE trades at $31.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas XENE's P/E ratio is -10.06. In terms of profitability, RXRX's ROE is -0.75%, compared to XENE's ROE of -0.32%. Regarding short-term risk, RXRX is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs IBRX Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, IBRX has a market cap of 2.4B. Regarding current trading prices, RXRX is priced at $5.19, while IBRX trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas IBRX's P/E ratio is -4.74. In terms of profitability, RXRX's ROE is -0.75%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, RXRX is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs PRVB Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, RXRX is priced at $5.19, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas PRVB's P/E ratio is -16.43. In terms of profitability, RXRX's ROE is -0.75%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, RXRX is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs LBPH Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, RXRX is priced at $5.19, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas LBPH's P/E ratio is -26.66. In terms of profitability, RXRX's ROE is -0.75%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, RXRX is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs DICE Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, RXRX is priced at $5.19, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas DICE's P/E ratio is -21.91. In terms of profitability, RXRX's ROE is -0.75%, compared to DICE's ROE of +0.56%. Regarding short-term risk, RXRX is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs ARWR Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, ARWR has a market cap of 2.2B. Regarding current trading prices, RXRX is priced at $5.19, while ARWR trades at $16.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas ARWR's P/E ratio is -12.97. In terms of profitability, RXRX's ROE is -0.75%, compared to ARWR's ROE of -0.47%. Regarding short-term risk, RXRX is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs LGND Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, LGND has a market cap of 2.2B. Regarding current trading prices, RXRX is priced at $5.19, while LGND trades at $113.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas LGND's P/E ratio is -15.66. In terms of profitability, RXRX's ROE is -0.75%, compared to LGND's ROE of -0.16%. Regarding short-term risk, RXRX is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs APLS Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, APLS has a market cap of 2.2B. Regarding current trading prices, RXRX is priced at $5.19, while APLS trades at $17.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas APLS's P/E ratio is -9.68. In terms of profitability, RXRX's ROE is -0.75%, compared to APLS's ROE of -1.00%. Regarding short-term risk, RXRX is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs CALT Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, RXRX is priced at $5.19, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas CALT's P/E ratio is -22.73. In terms of profitability, RXRX's ROE is -0.75%, compared to CALT's ROE of -1.67%. Regarding short-term risk, RXRX is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.
RXRX vs VCYT Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, VCYT has a market cap of 2.1B. Regarding current trading prices, RXRX is priced at $5.19, while VCYT trades at $27.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas VCYT's P/E ratio is 65.19. In terms of profitability, RXRX's ROE is -0.75%, compared to VCYT's ROE of +0.03%. Regarding short-term risk, RXRX is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs VCEL Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, VCEL has a market cap of 2.1B. Regarding current trading prices, RXRX is priced at $5.19, while VCEL trades at $42.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas VCEL's P/E ratio is 834.60. In terms of profitability, RXRX's ROE is -0.75%, compared to VCEL's ROE of +0.01%. Regarding short-term risk, RXRX is more volatile compared to VCEL. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs NAMS Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, NAMS has a market cap of 2.1B. Regarding current trading prices, RXRX is priced at $5.19, while NAMS trades at $18.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas NAMS's P/E ratio is -10.09. In terms of profitability, RXRX's ROE is -0.75%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, RXRX is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs DNLI Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, DNLI has a market cap of 2B. Regarding current trading prices, RXRX is priced at $5.19, while DNLI trades at $14.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas DNLI's P/E ratio is -5.28. In terms of profitability, RXRX's ROE is -0.75%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, RXRX is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs KNSA Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, KNSA has a market cap of 2B. Regarding current trading prices, RXRX is priced at $5.19, while KNSA trades at $27.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas KNSA's P/E ratio is -116.83. In terms of profitability, RXRX's ROE is -0.75%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, RXRX is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs CGON Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, CGON has a market cap of 2B. Regarding current trading prices, RXRX is priced at $5.19, while CGON trades at $25.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas CGON's P/E ratio is -17.30. In terms of profitability, RXRX's ROE is -0.75%, compared to CGON's ROE of -0.17%. Regarding short-term risk, RXRX is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs BCRX Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, BCRX has a market cap of 2B. Regarding current trading prices, RXRX is priced at $5.19, while BCRX trades at $9.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas BCRX's P/E ratio is -36.00. In terms of profitability, RXRX's ROE is -0.75%, compared to BCRX's ROE of +0.11%. Regarding short-term risk, RXRX is more volatile compared to BCRX. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs AGIO Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, AGIO has a market cap of 1.9B. Regarding current trading prices, RXRX is priced at $5.19, while AGIO trades at $33.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas AGIO's P/E ratio is 2.90. In terms of profitability, RXRX's ROE is -0.75%, compared to AGIO's ROE of +0.50%. Regarding short-term risk, RXRX is more volatile compared to AGIO. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs BLTE Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, BLTE has a market cap of 1.9B. Regarding current trading prices, RXRX is priced at $5.19, while BLTE trades at $58.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas BLTE's P/E ratio is -43.41. In terms of profitability, RXRX's ROE is -0.75%, compared to BLTE's ROE of -0.32%. Regarding short-term risk, RXRX is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.
RXRX vs IRON Comparison
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2B. In comparison, IRON has a market cap of 1.9B. Regarding current trading prices, RXRX is priced at $5.19, while IRON trades at $53.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.79, whereas IRON's P/E ratio is -14.01. In terms of profitability, RXRX's ROE is -0.75%, compared to IRON's ROE of -0.23%. Regarding short-term risk, RXRX is more volatile compared to IRON. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.